Prostate cancer (PCa) is the most common cancer in men. Androgen receptor axis plays a crucial role in the carcinogenesis of PCa. The mainstay treatment of prostate cancer is blockage of androgen receptor axis but in a vast majority of patient resistance
Emre Yekedüz +3 more
doaj +1 more source
The androgen receptor CAG repeat polymorphism and modification of breast cancer risk in BRCA1 and BRCA2 mutation carriers [PDF]
<p>Introduction: The androgen receptor (AR) gene exon 1 CAG repeat polymorphism encodes a string of 9–32 glutamines. Women with germline BRCA1 mutations who carry at least one AR allele with 28 or more repeats have been reported to have an earlier ...
Antoniou, A.C. +88 more
core +3 more sources
Method of treatment of prostate cancer with androgen receptor and glucocorticoid receptor antagonists [PDF]
Methods are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists.
core
The Effects of Serotonin Receptor Antagonists on Contraction and Relaxation Responses Induced by Electrical Stimulation in the Rat Small Intestine [PDF]
Background: The main source of 5-HT in body is in enterchromafin cells of intestine, different studies mentioned different roles for endogenous 5-HT and receptors involved and it is not clearified the mechanism of action of endogenous 5-HT. Objectives:
Javid, Farideh A. +2 more
core +4 more sources
Androgen receptor antagonists for prostate cancer therapy [PDF]
Androgen deprivation is the mainstay therapy for metastatic prostate cancer (PCa). Another way of suppressing androgen receptor (AR) signaling is via AR antagonists or antiandrogens. Despite being frequently prescribed in clinical practice, there is conflicting evidence concerning the role of AR antagonists in the management of PCa.
Christine, Helsen +6 more
openaire +2 more sources
Methods of treating castration-resistant prostate cancer with glucocorticoid receptor antagonists and anti-androgen receptor therapy [PDF]
Embodiments of the invention are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant
core
The CAG trinucleotide repeat length in the androgen receptor does not predict the early onset of prostate cancer [PDF]
Objective To relate the repeat length of the androgen-receptor CAG trinucleotide to the age of onset of prostate cancer, stage and grade of disease. Patients and methods After obtaining ethical approval, 265 patients with locally confined or locally ...
Paterson, P.J. +5 more
core +1 more source
Androgen receptor acetylation governs trans activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression function [PDF]
This work was supported by grants from the NIH (R01CA86072 to R.G.P. and R01CA72038-01 to S.A.W.F.) and The Susan Komen Breast Cancer Foundation (to R.G.P.). R.T.H. and E.J. were supported by the Medical Research Council. Y.-G.Y.
Wang, Jian +13 more
core +2 more sources
Transcriptional regulation of prostate kallikrein-like genes by androgen. [PDF]
Using gene-specific synthetic oligonucleotides the expression and regulation of kallikrein-like genes in the human prostatic cancer cell line LNCaP were studied.
Schulz, Peter +2 more
core +1 more source
Background Hormone therapy is the standard of care for newly diagnosed or recurrent prostate cancers. It uses anti-androgen agents, castration, or both to eliminate cancer promoting effect of testicular androgen. The p53 tumor suppressor controls a major
Packman Kathryn +6 more
doaj +1 more source

